Lenvatinib in patients with advanced HCC after first-line atezo/ beva Journal of Hepatology doi.org/10.1016/j.jhep… 🔎50 pts🇰🇷, phs II 👉ORR: 14% 👉mPFS: 5.4 mo 👉mOS: 9.8 mo 🧐All TKI somewhat effective after ICI 1st line, no clear winner so far ESMO - Eur. Oncology EASL Education ILCA

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in The Lancet Oncology Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered thelancet.com/journals/lanon…

Hepatocellular carcinoma is the 6th most common malignancy worldwide. Evolving treatments—including surgery, locoregional therapy, and immunotherapy—may offer curative options for advanced disease. More on HCC at: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… Michael Lidsky, MD, FACS Dimitrios Moris MD, MSc, PhD

Thrilled to share our latest work: Clinical utility of the peritoneal pathologic regression in gastric cancer patients associated to peritoneal metastasis. a study protocol degruyterbrill.com/document/doi/1… Fundación CTIC Paul H Sugarbaker Maria Eugenia Manrique Acevedo 🇨🇴 Carlos Bonilla 🇨🇴 Peritoneal Surface Oncology Group International Asociación Peritoneum

Current USPSTF guidelines for cancer screening. American Cancer Society guidelines for breast ca annual screening starting age 40 can be an “option”. ACS also endorses colonoscopy at 45y/o for colon ca! For ⬆️ risk breast ca & CRC, consider earlier screening! #OncTwitter #MedTwitter

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer NEJM doi.org/10.1056/NEJMdo… 👉Low-dose aspirin resulted in a significantly lower risk of recurrence w/ hotspot mutations 👉similar benefit w/ other alterations in PI3K pathway 🧐I would take it... ESMO - Eur. Oncology

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer Annals of Oncology doi.org/10.1016/j.anno… 👉Implementation of CEA and/or CT-scan surveillance did not provide any benefit in 5-year OS in stage II or III CRC ESMO - Eur. Oncology

Estupendo manuscrito acerca de las estrategias clave para la Prevención del cáncer gástrico y colorrectal: impacto centrado en mejorar la supervivencia. Unidad Funcional de Tumores Gastrointestinales del CTIC. Juliana Rendón et al. Academia Nacional de Medicina Investigación CTIC Juan-Manuel Anaya

La sabiduría popular enseña: “nada se olvida tan rápido como un favor, ni tal despacio como una ofensa”. Matemáticamente: los primeros a ritmo exponencial, las segundas a ritmo logarítmico.

In our discussion with Heloisa Soares MD and Ken Herrmann, we touched on the role of PRRT in NETs. A few key studies to keep in mind (⬆️PFS): - #COMPETE - #COMPOSE - #NETTER1 - #NETTER2 #OncTwitter #MedTwitter #gism

Neoadjuvant CTLA-4/PD-(L)1 vs Surgery +/-TTx in MSI Resectable Gastroesophageal Adenocarcinoma Journal of Clinical Oncology doi.org/10.1200/JCO-25… 🔎Patient Data Pooled Analysis: 197 pts, 49 ICIs, 27 FLOT 👉ICIs increase pCR & downstaging vs FLOT 🧐rationale for organ-sparing surgery or

~2 wks to #ESMO25! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge #OncTwitter ESMO - Eur. Oncology OncoAlert

Endoscopic or surgical #gastroenterostomy for palliation malignant gastric outlet obstruction? 🚀Today The Lancet Gastroenterology & Hepatology: #ENDURO randomised multicenter trial DPCG 🇳🇱 Excellent nationwide collaboration #surgery & #gastroenterology 🙌 ⏩️ sciencedirect.com/science/articl…

Es un verdadero orgullo recibir la designación del CTIC como centro integral para la atención del cáncer de la ESMO. Ha sido el esfuerzo mancomunado de muchos a favor de generar un espacio dedicado a la atención humanizada, para el desarrollo académico y la producción científica

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202) Journal of Clinical Oncology doi.org/10.1200/JCO-24… 👉Benefit but not sufficient for further development ESMO - Eur. Oncology

💥 New in JHEP Reports: review on second-line therapy after IO in HCC! jhep-reports.eu/article/S2589-… 💊 TKIs, IO rechallenge & novel targets (FGF19, GPC3) ⚖️ But head-to-head data still lacking…sequencing remains empirical 🤷🏻‍♂️ 🗺️ The map is expanding fast…yet the second-line

🔝 #ESMO25 #ColorectalCancer – Phase III CHALLENGE: Could structured exercise improve outcomes after adjuvant chemotherapy in stage II–III colon cancer? 🏃‍♂️ Exercise program + health education vs health education 🎯 DFS HR 0.72 (95% CI 0.55–0.94, p=0.017) 💥 OS HR 0.63 (95% CI